Christian Grøndahl Steps Down As CEO Of Kymab Chairman David Chiswell Takes Over As Interim CEO

Cambridge, UK, 9 February 2015: Kymab, a leader in the discovery and development of human therapeutic monoclonal antibodies generated using its unique discovery platform, today announces that, due to his family commitments, Dr Christian Grøndahl will be stepping down as Chief Executive Officer of Kymab with immediate effect. Dr David Chiswell, Kymab's Chairman, takes over as interim CEO until a new, permanent CEO is appointed.

Dr David Chiswell, Chairman and interim CEO of Kymab said: "On behalf of the Board of Directors, I would like to thank Christian for his significant contribution to Kymab. Under his leadership, the company has successfully raised $40m in a second funding round from two of the world's largest foundations, the Wellcome Trust and The Bill and Melinda Gates Foundation, providing a strong foundation on which Kymab can enter its next stage of growth. We wish him every success in his next venture. We look forward to continuing the implementation of Kymab's strategy in building a substantial global biopharmaceutical company."


About Kymab

Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse antibody platform.

Kymouse has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics. Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. The first Kymouse partnership agreement was concluded with Novo Nordisk in 2013.

Founded in 2009, Kymab has raised over $70m of equity financing from the Wellcome Trust and the Bill & Melinda Gates Foundation. It has an experienced management team with a successful track record in drug discovery and development and has 12 current therapeutic antibody discovery programmes in immune-oncology, auto-immunity, haematology, chronic pain, dyslipidaemia and cardiovascular diseases. Kymab, Kymouse, Kymab Access are trademarks of Kymab Limited.

For further information contact:

Hume Brophy
Mary Clark
Tel: +44 (0)20 3440 5653, Email: [email protected]

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.